Prognostic significance of peripheral and tumor-infiltrating lymphocytes in newly diagnosed stage III/IV non-small-cell lung cancer

被引:0
作者
Li, Fenge [1 ,2 ]
Tian, Chong [3 ,4 ,5 ]
Wang, Yupeng [1 ]
Wu, Huancheng [6 ]
Jin, Mengli [2 ]
Du, Xueming [1 ]
Yan, Jin [1 ]
Yang, Xueling [3 ]
Yu, Haipeng [3 ]
机构
[1] Tianjin Beichen Hosp, Dept Oncol, Tianjin, Peoples R China
[2] Tianjin Beichen Hosp, Core Lab, Tianjin, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Intervent Therapy, Tianjin, Peoples R China
[4] Tianjin Med Univ Inst & Hosp, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China
[5] Tianjin Med Univ Canc Inst & Hosp, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[6] Tianjin Beichen Hosp, Dept Neurosurg, Tianjin, Peoples R China
关键词
tumor-infiltrating lymphocytes; lung cancer; survival; peripheral lymphocytes; newly diagnosed;
D O I
10.3389/fmed.2024.1349178
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aim Lymphocytes are effector cells that fight cancer by killing tumor cells. Here, we aim to explore the prognostic significance of both peripheral and tumor-infiltrating lymphocytes (TILs) in newly diagnosed stage III/IV non-small-cell lung cancer (NSCLC). Materials and methods In total, 105 cases of newly diagnosed stage III/IV NSCLC from July 2017 to October 2022 at the Tianjin Beichen Hospital were retrospectively investigated. Peripheral blood samples at the time of diagnosis and tumor tissue slices from these patients were collected. General peripheral blood cell composition and TILs were measured and analyzed via an automatic blood analyzer and immunofluorescence staining analysis. The overall survival (OS) time of all patients was also obtained and analyzed. Results The median overall survival (mOS) of all patients is 12 months. The 1-, 2-, and 3-year overall survival rates were 60.5, 28.4, and 18.6%, respectively. Peripheral lymphocyte and neutrophil percentages, serum C-reactive protein (CRP) expression, tumor size, and tumor pathology are the prognostic factors of OS for newly diagnosed stage III/IV NSCLC patients. Moreover, patients with high tumor CD4+ and CD8+ T cell infiltration survived significantly longer compared to patients with low tumor CD4+ and CD8+ T cell infiltration (p < 0.0001 and p = 0.011, respectively). Compared to low tumor CD33+ cell infiltration, high tumor CD33+ cell infiltration was associated with worse OS (p = 0.018). High tumor CD8+ T cell infiltration was associated with lower peripheral lymphocyte number, lower serum CRP expression, smaller tumor size, and better tumor pathology (p = 0.012, p = 0.040, p = 0.012, and p = 0.029, respectively). Conclusion Increased numbers of peripheral lymphocytes, CD33+ cells, CD4+ TILs, and CD8+ TILs were significantly associated with OS in newly diagnosed stage III/IV NSCLC patients, which were positively associated with several basic clinical factors.
引用
收藏
页数:9
相关论文
共 30 条
[1]   Innovation in BCMA CAR-T therapy: Building beyond the Model T [J].
Banerjee, Rahul ;
Lee, Sarah S. ;
Cowan, Andrew J. .
FRONTIERS IN ONCOLOGY, 2022, 12
[2]   Prognostic Significance of CD4+and CD8+Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis [J].
Borsetto, Daniele ;
Tomasoni, Michele ;
Payne, Karl ;
Polesel, Jerry ;
Deganello, Alberto ;
Bossi, Paolo ;
Tysome, James R. ;
Masterson, Liam ;
Tirelli, Giancarlo ;
Tofanelli, Margherita ;
Boscolo-Rizzo, Paolo .
CANCERS, 2021, 13 (04) :1-15
[3]   Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer [J].
Cheng, Bo ;
Ding, Kaikai ;
Chen, Pengxiang ;
Ji, Jianxiong ;
Luo, Tao ;
Guo, Xiaofan ;
Qiu, Wei ;
Ma, Chunhong ;
Meng, Xue ;
Wang, Jian ;
Yu, Jinming ;
Liu, Yuan .
CANCER COMMUNICATIONS, 2022, 42 (01) :17-36
[4]   Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial [J].
Creelan, Benjamin C. ;
Wang, Chao ;
Teer, Jamie K. ;
Toloza, Eric M. ;
Yao, Jiqiang ;
Kim, Sungjune ;
Landin, Ana M. ;
Mullinax, John E. ;
Saller, James J. ;
Saltos, Andreas N. ;
Noyes, David R. ;
Montoya, Leighann B. ;
Curry, Wesley ;
Pilon-Thomas, Shari A. ;
Chiappori, Alberto A. ;
Tanvetyanon, Tawee ;
Kaye, Frederic J. ;
Thompson, Zachary J. ;
Yoder, Sean J. ;
Fang, Bin ;
Koomen, John M. ;
Sarnaik, Amod A. ;
Chen, Dung-Tsa ;
Conejo-Garcia, Jose R. ;
Haura, Eric B. ;
Antonia, Scott J. .
NATURE MEDICINE, 2021, 27 (08) :1410-+
[5]   Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis [J].
Dafni, U. ;
Michielin, O. ;
Lluesma, S. Martin ;
Tsourti, Z. ;
Polydoropoulou, V. ;
Karlis, D. ;
Besser, M. J. ;
Haanen, J. ;
Svane, I. -M. ;
Ohashi, P. S. ;
Kammula, U. S. ;
Orcurto, A. ;
Zimmermann, S. ;
Trueb, L. ;
Klebanoff, C. A. ;
Lotze, M. T. ;
Kandalaft, L. E. ;
Coukos, G. .
ANNALS OF ONCOLOGY, 2019, 30 (12) :1902-1913
[6]   Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer [J].
Feng, Wen ;
Li, Yuan ;
Shen, Lei ;
Cai, Xu-Wei ;
Zhu, Zheng-Fei ;
Chang, Jian-Hua ;
Xiang, Jia-Qing ;
Zhang, Ya-Wei ;
Chen, Hai-Quan ;
Fu, Xiao-Long .
ONCOTARGET, 2016, 7 (06) :7227-7240
[7]   Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis [J].
Gao, Guoxuan ;
Wang, Zihan ;
Qu, Xiang ;
Zhang, Zhongtao .
BMC CANCER, 2020, 20 (01)
[8]   SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery [J].
Hu-Lieskovan, Siwen ;
Bhaumik, Srabani ;
Dhodapkar, Kavita ;
Grivel, Jean-Charles J. B. ;
Gupta, Sumati ;
Hanks, Brent A. ;
Janetzki, Sylvia ;
Kleen, Thomas O. ;
Koguchi, Yoshinobu ;
Lund, Amanda W. ;
Maccalli, Cristina ;
Mahnke, Yolanda D. ;
Novosiadly, Ruslan D. ;
Selvan, Senthamil R. ;
Sims, Tasha ;
Zhao, Yingdong ;
Maecker, Holden T. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[9]   Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints [J].
Hudry, Delphine ;
Le Guellec, Solenn ;
Meignan, Samuel ;
Becourt, Stephanie ;
Pasquesoone, Camille ;
El Hajj, Houssein ;
Martinez-Gomez, Carlos ;
Leblanc, Eric ;
Narducci, Fabrice ;
Ladoire, Sylvain .
CANCERS, 2022, 14 (21)
[10]   Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. [J].
Jazaeri, Amir A. ;
Zsiros, Emese ;
Amaria, Rodabe Navroze ;
Artz, Andrew S. ;
Edwards, Robert P. ;
Wenham, Robert Michael ;
Slomovitz, Brian M. ;
Walther, Axel ;
Thomas, Sajeve Samuel ;
Chesney, Jason Alan ;
Morris, Robert ;
Matsuo, Koji ;
Gaillard, Stephanie ;
Rose, Peter Graham ;
Garcia Donas, Jesus ;
Tromp, Jacqueline Maria ;
Tavakkoli, Fatemeh ;
Li, Huiling ;
Fardis, Maria ;
Monk, Bradley J. .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)